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Background: α-Dystroglycan undergoes extensive 
glycosylation required for the interaction between 
α-dystroglycan and its ligands such as laminin. 
Results: HNK-1ST suppressed the glycosylation 
and reduced the ligand-binding activity of 
α-dystroglycan. 
Conclusion: The sulfotransferase activity of 
HNK-1ST is essential for the modulation of 
α-dystroglycan. 
Significance: This study identifies a novel role for 
HNK-1ST as a regulator of the functional glycans on 
α-dystroglycan other than HNK-1 biosynthesis. 
 
SUMMARY 
     Retinoic acid (RA) is a well-established 
anti-tumor agent inducing differentiation in 
various cancer cells. Recently, a robust 
up-regulation of human natural killer-1 
sulfotransferase (HNK-1ST) was found in several 
subsets of melanoma cells during RA-mediated 
differentiation. However, the molecular 
mechanism underlying the tumor suppression 
mediated by HNK-1ST remains unclear. Here we 
show that HNK-1ST changed the glycosylation 
state and reduced the ligand-binding activity of 
α-dystroglycan (α-DG) in RA-treated S91 
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melanoma cells, which contributed to an 
attenuation of cell migration. Knockdown of 
HNK-1ST restored the glycosylation of α-DG and 
the migration of RA-treated S91 cells, indicating 
that HNK-1ST functions through glycans on 
α-DG. Using CHO-K1 cells, we provide direct 
evidence that HNK-1ST but not other 
homologous sulfotransferases (C4ST1 and 
GalNAc4ST1) suppresses the glycosylation of 
α-DG. Activity-abolished mutant of HNK-1ST 
did not show the α-DG-modulating function, 
indicating that the sulfotransferase activity of 
HNK-1ST is essential. Finally, the 
HNK-1ST-dependent incorporation of 
35[S]-sulfate groups was detected on α-DG. These 
findings suggest a novel role for HNK-1ST as a 
tumor-suppressor controlling the functional 
glycans on α-DG, and the importance of 
sulfate-transfer in the glycosylation of α-DG. 
 
     Invasiveness is a hallmark of malignant 
tumors. In the initial phase of invasion, cell-cell 
and/or cell-extracellular matrix (ECM) interactions 
are crucial (1). The external region of a cell 
membrane, known as the glycocalyx, is dominated 
by glycosylated molecules, which have important 
roles in these interactions (2). Therefore, the aberrant 
expression of various genes involved in glycan 
synthesis or degradation, which causes 
compositional changes of the glycocalyx, is 
frequently associated with malignant transformation 
(3-5). Recently, Zhao et al. reported the expression of 
human natural killer-1 sulfotransferase (HNK-1ST) 
to be strongly up-regulated in several subsets of 
murine and human melanoma cells during retinoic 
acid (RA)-mediated differentiation (6). The 
expression of HNK-1ST is activated via an RA 
receptor-γ pathway, and the invasiveness of 
melanoma cells is suppressed along with HNK-1ST 
induction (6). HNK-1ST is a sulfotransferase 
involved in the biosynthesis of the HNK-1 
carbohydrate, a neural glyco-epitope exhibiting 
abundant expression during brain development (7). 
Although HNK-1ST has the potential to control the 
cell surface expression of the HNK-1 carbohydrate, 
it is not clear how HNK-1ST is associated with the 
tumor-suppressive function. 
     We have demonstrated that the HNK-1 
carbohydrate is required for the structural and 
functional development of the mammalian nervous 
system, such as the maturation of dendritic spines 
and acquisition of synaptic plasticity, respectively 
(8-10). The HNK-1 carbohydrate has a unique 
structural feature, i.e., a sulfated glucuronic acid is 
attached to the non-reducing terminal of an 
N-acetyllactosamine residue (11,12). Because the 
N-acetyllactosamine structure is commonly found in 
various glycoproteins and glycolipids, two 
glucoronyltransferases (GlcAT-P and GlcAT-S) and 
a sulfotransferase (HNK-1ST) had been cloned and 
characterized as key enzymes for the biosynthesis. 
(7). GlcAT-P or GlcAT-S and HNK-1ST interact 
closely as a functional complex, cooperatively 
synthesizing the HNK-1 carbohydrate (13). 
However, while GlcAT-P and GlcAT-S show a 
highly restricted tissue distribution (14,15), 
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HNK-1ST is more ubiquitous and exists in several 
tissues where neither GlcAT-P nor GlcAT-S is 
observed, including skeletal muscle, heart, spleen, 
and reproductive organs (16,17). These findings 
suggest that HNK-1ST has another function, which 
might underlie the RA-mediated melanoma 
differentiation. 
     α-Dystroglycan (α-DG) is a ubiquitously 
expressed peripheral membrane glycoprotein, which 
serves as a receptor for ECM components including 
laminin, agrin and perlecan (18,19). α-DG is 
anchored on the plasma membrane by β-DG, which 
interacts with cytoskeletal proteins, together 
comprising the DG complex that provides physical 
links between the cell and basal lamina (18-20). 
α-DG undergoes extensive glycosylation in a 
tissue-specific manner (18,19,21), and the attached 
glycan acts as a critical mediator of the interaction 
between α-DG and its ligands (22,23). Although the 
precise structure of the glycan important for the 
function of α-DG has not completely been 
determined, aberrant glycosylation of α-DG has 
already been identified in the pathogenesis of several 
types of congenital muscular dystrophy (CMD) 
accompanied by brain and eye malformations 
(24,25). In CMD patients, mutations in six known or 
putative glycosyltransferases involved in the 
biosynthesis of O-mannosyl glycan, including 
protein O-mannosyl transferase 1 (POMT1), 
POMT2, protein O-mannose β-1, 
2-N-acetylglucosaminyltransferase 1 (POMGnT1), 
fukutin, fukutin-related protein (FKRP), and 
like-acetylglucosaminyltransferase (LARGE) have 
been found (26-31). These observations indicate that 
O-mannosyl modification is essential for the 
functional glycosylation of α-DG. Furthermore, 
altered glycosylation of α-DG is also implicated in 
epithelium-derived cancer progression, 
demonstrating the involvement of α-DG in 
tumorigenic phenotypes (32,33). 
     In this report, we show that HNK-1ST 
induced in RA-treated S91 melanoma cells 
suppressed the glycosylation and ligand-binding 
activity of α-DG. The functional loss of α-DG 
resulted in a reduction in cell migration. Using 
CHO-K1 cells, we provide direct evidence that 
HNK-1ST actually has the ability to inhibit the 
synthesis of glycans on α-DG, suppressing the 
interaction between α-DG and laminin. Furthermore, 
the HNK-1ST-dependent incorporation of sulfate 
groups was detected on α-DG. These results suggest 
a novel tumor-suppressive role for HNK-1ST, which 




     cDNA construction - For α-DG-Fc, the coding 
sequence of human α-DG was amplified by PCR 
with primers 
ACGATCGATGCCACCATGAGGATGTCTGT 
(with ClaI site) and 
CCGACTAGTACTCACCGCCCCGGGTGATAT
TCTGCA (with SpeI site) using pcDNA3.1
containing human DAG1 cDNA as a template, and 
subcloned into pEF-Fc. Expression plasmids for 
FLAG-GlcAT-P, pIRES-GlcAT-P/HNK-1ST 
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(pIRES-P/ST), HNK-1ST-EGFP, C4ST1-EGFP and 
GalNAc4ST1-EGFP were described previously (13). 
For LARGE-myc, the full length cDNA of mouse 
LARGE was amplified from pBC SK+ containing 
mouse LARGE cDNA, which was provided by 
Kazusa DNA res. inst., using primers 
TCTGAGAGGATGCTGGGAAT and 
AAAGGGCCCCTGTTGTTCTCAGCTGTGAG 
(skipping stop codon, with ApaI site).  After the 
resulting fragment had been digested with ApaI, it 
was ligated to pcDNA3.1/myc-His B (Invitrogen), 
which had been digested with EcoRV and ApaI. 
Construction of R189A-EGFP, the plasmid encoding 
the R189A mutant of HNK-1ST, was described 
previously (34). 
 
     Cell culture and transfection - CHO-K1 cells 
were maintained in α-minimum essential medium 
with 10% fetal bovine serum (FBS) in 5% CO2 at 
37°C. S91 murine melanoma cells (a gift from Dr. A. 
Kurosaka, Kyoto Sangyo University), also known as 
M3, were maintained in Dulbecco’s modified eagle 
medium with 10% FBS in 5% CO2 at 37°C. For 
cDNA transfection, cells were grown overnight and 
transfected using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s instructions. To 
obtain the extracellularly secreted proteins, the 
culture medium was replaced with serum-free 
OPTI-MEM I (Invitrogen) after 5 h of incubation.  
 
     RA treatment - RA (all trans-retinoic acid, 
Sigma) was dissolved in DMSO, kept as a 10 mM 
stock solution at -20°C, and then diluted to the final 
concentration in the growth medium before being 
added to cells. Cells were harvested after 16 h for the 
RT-PCR analysis or after 48 h for Western blotting 
and the migration assay. 
 
     siRNA-mediated knockdown - siRNA 
oligonucleotides specific for mouse HNK-1ST and a 
negative control siRNA were obtained from Qiagen. 





oligonucleotides were transiently transfected using 
Lipofectamine RNAiMAX (Invitrogen) according to 
the manufacturer’s protocol. The culture medium 
was replaced with growth medium after 5 h of 
incubation. 
 
     Purification of recombinant α-DG-Fc - The 
culture medium and cells were collected at 48 h 
post-transfection. The cells were lysed with 
Tris-buffered saline (pH 7.4) containing 1% Triton 
X-100 and protease inhibitor mixture (Nakalai 
Tesque), and then the cell extracts were obtained by 
centrifugation. The culture medium and the cell 
extracts were incubated with protein G Sepharose 
(GE Healthcare) for 2 h at 4°C. The beads were 
washed extensively with phosphate-buffered saline 
(PBS) containing 0.1% Triton X-100 and the bound 




     Western blotting and laminin overlay assay - 
Proteins solubilized in LSB were separated by 
SDS-PAGE using 10% polyacrylamide gels and 
transferred to nitrocellulose membranes. After 
blocking with 5% nonfat dry milk in PBS containing 
0.05% Tween 20, the membranes were incubated 
with primary antibodies, followed by 
HRP-conjugated secondary antibodies. Protein 
bands were detected with Super Signal West Pico 
chemiluminescence reagent (Thermo Scientific) 
using a LAS-3000 Luminoimage Analyzer 
(FUJIFILM). The following primary antibodies were 
used; HNK-1 mAb (a hybridoma cell line was 
purchased from American Type Culture Collection); 
M6749 mAb (against a non-sulfated form of the 
HNK-1 carbohydrate, a gift from Dr. H. Tanaka, 
Kumamoto University); GP2 pAb (a rabbit 
anti-GlcAT-P pAb raised against the catalytic region 
of the recombinant human GlcAT-P); anti-Fc pAb 
(Jackson Immunoresearch); anti-EGFP mAb 
(Clontech); anti-myc mAb and IIH6 mAb 
(Millipore); anti-laminin pAb and anti-FLAG pAb 
(Sigma); anti-β-DG mAb (Novocastra); α-DG core 
pAb (goat polyclonal antibody against the C-terminal 
domain of the α-DG polypeptide) (35); and 
anti-GAPDH mAb (Calbiochem). For the laminin 
overlay assay, nitrocellulose membranes with 
transferred proteins were blocked with 
laminin-binding buffer (LBB; 20 mM Tris-HCl, pH 
7.4, 150 mM NaCl, 1 mM CaCl2 and 1mM MgCl2,) 
containing 5% nonfat dry milk. After being washed 
in LBB, the membranes were incubated with 1 
µg/ml laminin-1 (Sigma) diluted with LBB 
containing 3% bovine serum albumin (BSA) for 90 
min. at room temperature. Bound laminin-1 was 
detected using anti-laminin antibody by 
immunoblotting as described above. For the 
quantification of the intensity of the protein bands, 
densitometric analyses were performed using image 
analysis software ImageGauge (FUJIFILM). 
 
     Biotinylation of cell surface proteins - Cells 
cultured in 60-mm dishes were washed twice with 
ice-cold PBS and incubated with 1 mg/ml EZ-link 
Sulfo-NHS-SS-biotin (Thermo Scientific) in PBS for 
30 min at 4°C. Cells were washed twice with PBS 
and lysed with Tris-buffered saline (pH 7.4) 
containing 1% Triton X-100 and protease inhibitor 
mixture, and then the cell extracts were obtained by 
centrifugation. Then, biotinylated proteins were 
precipitated with immobilized streptavidin (Thermo 
Scientific) and analyzed by Western blotting as 
described above. 
 
     Radioactive metabolic labeling - CHO cells 
were grown overnight in 25 cm2 cell culture flasks 
under normal conditions. At 5 h post-transfection, 
the culture medium was replaced with sulfate-free 
M8028 MEM (Sigma), and incubation was 
continued for 1 h. Then, cells were labeled with 30 
µCi/ml of [35S]-sodium sulfate (ARC Inc.). The 
culture medium was collected after two overnight of 
labeling and incubated with protein G Sepharose for 
2 h. Bound proteins were separated by SDS-PAGE, 
transferred to nitrocellulose membranes and then 
subjected to autoradiography or Western blotting 
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using anti-Fc pAb. 
 
     RNA isolation and RT-PCR - S91 cells were 
harvested and homogenized in TRIzol (Invitrogen), 
and extracted with chloroform and isopropanol. The 
RNA was dissolved in RNase-free water. One 
microgram of total RNA was digested with DNaseI 
and then converted to cDNA using SuperScriptII 
(Invitrogen). The following primer pairs were used 


















Quantitative PCR was performed with a Chromo 4 
Real-Time System (Bio-Rad) using SYBR green I. 
Each sample was run in triplicate and GAPDH 
mRNA was amplified from the same sample to 
normalize the expression level. 
 
     Migration assays - Cell migration was assayed 
using 24-well transwell plates (8 µm pore size) (BD 
Biosciences) according to the manufacturer’s manual. 
Prior to the assay, S91 cells were treated with 1 µM 
RA or 0.1% DMSO for 48 h and the insert 
membranes were coated with laminin-1 (10 µg/ml) 
(BD Biosciences). Then, 1x105 S91 cells suspended 
in serum-free DMEM were seeded into the upper 
chamber, and DMEM supplemented with 10% FCS 
was placed in the lower chamber. 1 µM RA or 0.1% 
DMSO was added to both chambers during the 
migration period. After 24 h, the inserts were fixed in 
ice-cold methanol and non-migrating cells were 
removed from the upper surface of the membrane. 
The inserts were stained in 0.1% Toluidine Blue O 
solution for 15 minutes and washed two times with 
PBS. The membranes were cut and mounted on 
glass slides. Five Randomly selected fields per 
membrane were counted, and the average was 
shown as the migrated cell number.  
 
     Immunofluorescence - Cells were washed with 
PBS, fixed with 4% paraformaldehyde for 15 
minutes at room temperature and then incubated 
with primary antibodies, followed by Alexa 
Fluor-conjugated secondary antibodies. For 
permeabilization of the plasma membrane, cells 
were incubated with PBS containing 3% BSA and 
0.1% Triton X-100 for 15 minutes after the fixation. 
Immunofluorescent images were acquired by a 
Fluoview laser confocal microscope system 
(Olympus). The following antibodies were used; 
IIH6 mAb (Millipore); anti-HIS pAb (Santa Cruz 
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Biotechnology); GM130 mAb (BD Biosciences); 
and anti-β-DG mAb (Novocastra).  
 
     Statistics - Statistical significance was 
determined by a two-tailed Student’s t-test for 
comparisons between two groups, and by an analysis 
of variance (ANOVA) with Ryan’s test for 
comparisons among multiple groups. 
 
RESULTS 
     Specific induction of HNK-1ST expression and 
alternate glycosylation of α-DG in RA-treated 
melanoma cells - To investigate whether HNK-1ST 
governs tumor-related phenotypes of melanoma cells 
via production of the HNK-1 carbohydrate or not, 
we evaluated the mRNA expression of the enzymes 
synthesizing HNK-1 in S91 murine melanoma cells, 
which undergo RA-mediated differentiation (6,36). 
Following treatment with 1 µM RA, a marked 
increase of HNK-1ST mRNA was detected using 
RT-PCR (Fig. 1, A and B), consistent with a 
previous report (6). However, neither of the 
glucuronyltransferases (GlcAT-P and GlcAT-S) 
responsible for producing HNK-1 was observed (Fig. 
1A), suggesting the absence of the HNK-1 
carbohydrate in S91 cells. To confirm this notion, we 
examined the expression of the HNK-1 carbohydrate 
in S91 cells treated with DMSO or RA using a 
HNK-1 monoclonal antibody (mAb). As expected, 
HNK-1 carbohydrate was not detected even in 
RA-treated cells (Fig. 1C). As we previously 
reported that the HNK-1 mAb specifically 
recognizes sulfated form of HNK-1 epitope but not 
non-sulfated one (17), we tried to examined whether 
sulfated form of HNK-1 epitope was expressed in 
S91 cells by the transfection of GlcAT-P. As 
expectedly, HNK-1 immunoreactivity was detected 
by GlcAT-P transfection, suggesting that a 
functional HNK-1ST was expressed in the cells (Fig. 
1C). These results indicate that HNK-1ST acts solely 
as a tumor-suppressor and its function is independent 
of HNK-1 biosynthesis. 
     It has been demonstrated that α-DG, especially 
the glycan attached to it, is involved in tumor 
invasiveness in various cancer types such as breast, 
prostate, and lung carcinomas (32,33). Since 
HNK-1ST associates with the modification of 
glycans, up-regulation of HNK-1ST expression 
might affect the glycosylation in cells. Hence, we 
speculated that RA treatment causes a compositional 
change in the glycan on α-DG, leading to a 
suppression of melanoma invasiveness. To test this 
possibility, we explored the involvement of α-DG in 
the migratory behavior of S91 cells using a transwell 
migration assay with laminin-coated membranes. 
The RA-treated cells showed significantly decreased 
migration (Fig. 1D), which confirmed the anti-tumor 
effect of RA. Intriguingly, on the addition of an IIH6 
mAb, which recognizes the laminin-binding glycan 
on α-DG and can disturb the α-DG-ligand interaction 
(23), S91 cells showed substantially reduced 
migration (Fig. 1D). Moreover, RA treatment 
eliminated the susceptibility to the IIH6 mAb (Fig. 
1D). These findings suggest that the glycan 
recognized by IIH6 on α-DG positively regulates the 
motility of control S91 cells and the reduced motility 
8 
in RA-treated cells is due to the glycosylation state of 
α-DG. Then, we employed biochemical analyses to 
clarify the functional alteration of α-DG caused by 
RA. α-DG was enriched from RA-treated cells using 
cell surface biotinylation and subjected to a laminin 
overlay assay and immunoblotting with the IIH6 
mAb. RA-treated S91 cells exhibited considerably 
decreased laminin-binding activity of α-DG (to 
43.8%) and drastically reduced IIH6 
immunoreactivity (to 14.5%) (Fig. 1E and 
supplemental Fig. S1A). The expression of α-DG 
core protein and β-DG was unaltered by RA (Fig. 
1E), indicating that the treatment resulted in a change 
in the glycosylation of α-DG, but not in the cell 
surface abundance of α-DG itself. 
Immunofluorescence analyses also demonstrated 
RA-dependent disappearance of the IIH6 epitope, 
which intrinsically localized on the plasma 
membrane of S91 cells (Fig. 1F). While the precise 
glycan structure recognized by the IIH6 mAb is still 
unknown, LARGE, a putative glycosyltransferase, is 
one of the most potent inducers of the IIH6-positive 
laminin-binding glycan on α-DG (37,38). The 
IIH6-positive laminin-binding glycan on α-DG was 
induced by the transfection of LARGE in S91 cells 
(supplemental Fig. S2, A and B). However, RA 
treatment eliminated the generation of the IIH6 
epitope even in cells overexpressing LARGE 
(supplemental Fig. S2, A and B). Taken together, 
these results revealed that RA had a strong effect 
inducing a functional change of α-DG by altering its 
glycosylation, which contributed at least in part to 
the RA-mediated suppression of cell motility.  
 
     Involvement of HNK-1ST in functional glycan 
synthesis on α-DG and cell migration - In DMSO 
and RA-treated S91 cells, the expression patterns of 
α-DG and various glycosyltransferases involved in 
the synthesis of laminin-binding glycan and IIH6 
epitope were unchanged (Fig. 2A). Therefore, we 
sought the role of HNK-1ST, which showed 
dynamic induction by RA, as a key determinant 
controlling α-DG glycosylation. To examine whether 
the RA-dependent regulation of α-DG was mediated 
by HNK-1ST, we performed knockdown analyses of 
HNK-1ST using siRNA. Two different siRNAs 
against HNK-1ST (si-ST1 and 2) were used. Western 
blot analysis showed that both si-ST1 and 2 
substantially restored the laminin-binding activity 
(from 46.4% to 77% and 60.3%) and IIH6 epitope of 
α-DG (from 19.1% to 60% and 42.7%) in 
RA-treated S91 cells, compared with the control 
siRNA (si-Cont) (Fig. 2B and supplemental Fig. 
S1B). Then, we assessed the knockdown efficacy in 
siRNA-transfected cells by quantitative RT-PCR. 
Compared with the RA-treated control, the amount 
of HNK-1ST mRNA was reduced to 38.9% and 
47.1% in si-ST1 and 2-transfected cells, respectively 
(Fig. 2C). In contrast, forced expression of 
EGFP-tagged HNK-1ST effectively reduced the 
laminin-binding activity of α-DG and IIH6 epitope 
production regardless of LARGE-overexpression 
(Fig. 2D). Collectively, these analyses provide direct 
evidence that HNK-1ST negatively regulates the 
glycosylation of α-DG, which is a novel role for 
HNK-1ST as a functional regulator of α-DG. 
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Furthermore, we analyzed the effect of 
down-regulation of HNK-1ST on the migration of 
S91 cells. Using the transwell assay, both si-ST1 and 
2 were found to partially ameliorate the migration of 
RA-treated S91 cells (Fig. 2E). si-ST1 induced a 
much more effective recovery of migration than 
si-ST2, which was well correlated with the amount 
of IIH6 epitope shown in Fig. 2B, indicating 
significant involvement of this glyco-epitope in the 
migration of S91 cells. 
 
     Expression of HNK-1ST abrogates 
LARGE-dependent glycosylation on α-DG - 
HNK-1ST was found to have the potential to 
suppress the glycosylation by LARGE, prompting us 
to further investigate the functional interaction 
between HNK-1ST and LARGE in the 
glycosylation of α-DG. We generated an expression 
plasmid encoding α-DG fused to a human IgG Fc 
fragment (α-DG-Fc), which would be secreted into 
the culture medium. In addition to α-DG-Fc, 
LARGE-myc and HNK-1ST-EGFP were 
simultaneously transfected into CHO-K1 cells. 
α-DG-Fc was pulled down from the culture medium 
and analyzed by Western blotting. The extensive 
glycosylation induced by LARGE was detected by 
laminin overlay assay and immunoblotting with IIH6 
mAb, as a broad and high-molecular band (Fig. 3A). 
However, when α-DG-Fc was co-transfected with 
HNK-1ST-EGFP, there was a remarkable decrease 
in the laminin-binding activity and almost complete 
loss of IIH6 immunoreactivity, in spite of the 
comparable expression of LARGE-myc (Fig. 3, A 
and B). The results obtained from this simple 
expression system clearly demonstrated that 
HNK-1ST actually inhibits the formation of the 
glycan on α-DG. Furthermore, to explore whether a 
similar effect could be found with other homologous 
sulfotransferases, we co-transfected LARGE-myc 
and C4ST1-EGFP or GalNAc4ST1-EGFP, both of 
which belong to the HNK-1ST family (39,40). 
LARGE-dependent glycosylation of α-DG was not 
suppressed by either C4ST1 or GalNAc4ST1 (Fig. 4, 
A and B), indicating that the α-DG-modulating 
function is specific to HNK-1ST.  
 
     The interaction between α-DG and LARGE is 
unaltered in the presence of HNK-1ST - To 
investigate the molecular basis underlying the 
inhibitory effect of HNK-1ST on the glycosylation 
of α-DG, we tested the following two possibilities: 
that HNK-1ST, causing steric hindrance, prevents 
glycosyltransferases from approaching α-DG, and 
that HNK-1ST acts as a sulfotransferase to suppress 
the glycosylation of α-DG. First, we analyzed 
whether the interaction between α-DG and LARGE 
is attenuated in the presence of HNK-1ST because 
the interaction is a crucial step in the 
LARGE-dependent glycosylation of α-DG (41). We 
observed no significant change in the interaction 
between α-DG-Fc and LARGE-myc, regardless of 
HNK-1ST-EGFP expression (supplemental Fig. 
S3A), indicating that HNK-1ST does not cause steric 
hindrance. In addition, we confirmed that the 
subcellular localization of LARGE-myc in the Golgi 
apparatus (42) was unaltered by co-expression with 
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HNK-1ST-EGFP (supplemental Fig. S3B). 
 
     Sulfotransferase activity is prerequisite for 
HNK-1ST to modulate α-DG glycosylation - Next, 
we generated R189A-EGFP, a plasmid encoding a 
form of HNK-1ST that harbors a mutation of Arg189 
to Ala, exhibiting almost no enzymatic activity due 
to impaired binding to the donor substrate, 
3’-phosphoadenosine 5’-phosphosulfate (PAPS) 
(34,43). R189A-EGFP did not synthesize the 
HNK-1 carbohydrate when co-transfected with 
GlcAT-P, which confirmed the disappearance of its 
sulfotransferase activity (supplemental Fig. S4A). 
While showing no enzymatic activity, R189A-EGFP 
properly localized in the Golgi apparatus 
(supplemental Fig. S4B). Then, we utilized the 
mutant to determine the requirement of the 
sulfotransferase activity of HNK-1ST in the 
modulation of α-DG glycosylation. Judging from the 
laminin overlay assay and immunoblotting with IIH6 
mAb, R189A-EGFP did not suppress the 
LARGE-dependent modification (Fig. 5, A and B), 
indicating that sulfotransferase activity is essential 
for HNK-1ST to regulate the glycosylation of α-DG. 
To further confirm this evidence, we carried out an 
inhibition assay for PAPS production using sodium 
chlorate (NaClO3). NaClO3 is a specific inhibitor of 
ATP sulfurylase, an enzyme responsible for the 
production of PAPS in cells, resulting in depression 
of the intracellular sulfation (44). Treatment with 50 
mM NaClO3 obviously suppressed HNK-1 
carbohydrate synthesis, showing that sulfate-transfer 
is effectively abrogated in CHO-K1 cells 
(supplemental Fig. S5). As expected, NaClO3 
treatment considerably restored the 
LARGE-dependent glycosylation in 
HNK-1ST-EGFP-expressing cells (Fig. 5, C and D). 
Taken together, these results provide strong evidence 
that the sulfate-transfer induced by HNK-1ST plays 
a regulatory role in the formation of functional 
glycans on α-DG. 
 
     α-DG undergoes sulfate-transfer by HNK-1ST 
- Considering that HNK-1ST also suppressed the 
laminin-binding activity of α-DG in the absence of 
LARGE (Fig. 6A), we assumed that α-DG is the 
target of sulfation by HNK-1ST, rather than LARGE. 
Hence, to verify the incorporation of the sulfate 
moiety into α-DG, we labeled CHO-K1 cells with 
radioactive [35S]-sodium sulfate. The 
HNK-1ST-dependent incorporation of sulfate into 
α-DG-Fc was detected by autoradiography (Fig. 6B), 
suggesting that a sulfated glycan is generated by 
HNK-1ST on α-DG, which might have a crucial 




Melanoma is one of the most malignant tumors, 
showing high metastatic ability and a rapid 
progression, which leads to a poor prognosis. 
Expression of the HNK-1 epitope is found in both 
primary and metastatic lesions in cases of melanoma 
(45,46) and correlates with metastatic behavior (46). 
In addition, the HNK-1 carbohydrate positively 
affects the invasive and adhesive functions of 
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melanoma cells, demonstrating the relationship 
between HNK-1 expression and the aggressiveness 
of melanomas (47). Meanwhile, HNK-1ST, one of 
the enzymes producing the HNK-1 carbohydrate, 
was identified as a candidate suppressor for 
melanoma invasiveness by Zhao et al (6). Apparent 
confounding issues are that HNK-1ST functions as a 
tumor suppressor while the resulting product, the 
HNK-1 epitope, promotes metastasis. However, it 
should be noted that although Zhao et al. reported 
that HNK-1ST functions as a tumor suppressor, they 
failed to detect the HNK-1 epitope in 56 primary and 
20 metastatic melanomas (6). This means that 
HNK-1ST might regulate invasiveness through a 
HNK-1 epitope-independent pathway. As a possible 
solution to this problem, our findings revealed that 
α-DG-dependent migration is another mechanism of 
metastasis independent of the HNK-1 epitope. 
Furthermore, we disclosed here a novel role of 
HNK-1ST, the functional regulation of α-DG via 
post-translational modification. This distinct function 
of HNK-1ST does not require GlcAT-P and 
GlcAT-S (Fig. 3), which accounts for the absence of 
the HNK-1 epitope despite the expression of 
HNK-1ST. Moreover, HNK-1 is not constantly 
expressed in melanoma lesions or cell lines (45-47), 
indicating that there are at least two subpopulations 
of melanomas, i.e. HNK-1-positive and negative. 
Hence, α-DG-dependent migration controlled by 
HNK-1ST might predominate in HNK-1-negative 
melanomas. The unique glycan structure expressed 
on α-DG has been shown to have a close relationship 
to tumor-related phenotypes such as invasiveness 
(32,33). Previous studies reported that the IIH6 
mAb-reactive glycan of α-DG had a suppressive 
effect on tumor invasion in cases of breast, prostate, 
and lung carcinoma (32,33), while we obtained the 
opposite results using melanoma cells (Fig. 1 and 2), 
suggesting that the role of α-DG varies dependent on 
the type of cancer. Therefore, we found that 
HNK-1ST has a potential role modulating 
invasiveness by controlling the glycosylation of 
α-DG, leading to tumor suppression in melanoma 
cases. 
     Of particular interest was that overexpression 
or RA-mediated up-regulation of HNK-1ST did not 
completely abolish the laminin-binding activity of 
α-DG in S91 and CHO-K1 cells while 
IIH6-immunoreactivity disappeared in the same 
samples (Fig. 1-5). This suggests that sulfation by 
HNK-1ST evokes inhibitory effects predominantly 
on the IIH6 mAb-reactive glycan among the 
heterogeneous carbohydrate structures of α-DG, 
resulting in substantial laminin-binding activity of 
α-DG remaining. The IIH6-reactive epitope and 
laminin-binding glycan are known to somewhat 
overlap (23). However, whether these two moieties 
are identical or not is still unclear in spite of a 
number of structural analyses on the glycosylation of 
α-DG (48-50). Chiba et al. reported that a unique 
O-mannosyl tetrasaccharide on α-DG has the ability 
to bind to laminin (51). More recently, a novel 
phosphate-containing glycan was identified on α-DG 
(52). The phosphate is attached to the 6-O-position 
of O-linked mannose, and post-phosphoryl 
glycosylation mediated by LARGE is essential for 
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α-DG-ligand interaction and IIH6 epitope production 
(52). We demonstrated that LARGE could not 
generate the IIH6 epitope on α-DG in the presence of 
HNK-1ST (Fig. 3-5) and HNK-1ST indeed 
transferred a sulfate group onto α-DG (Fig. 6B), 
suggesting that HNK-1ST inhibits the 
LARGE-dependent post-phosphoryl modification of 
α-DG by sulfate-transfer. Therefore, identification of 
the specific site of α-DG sulfated by HNK-1ST and 
the structure of the resulting sulfated glycan might be 
important for elucidating LARGE-dependent 
glycosylation.  
     During the preparation of this manuscript, Dr. 
K. Campbell’s group reported that LARGE could act 
as a bifunctional glycosyltransferase with both 
xylosyl- and glucuronyltransferase activities and 
could generate a linear polysaccharide structure 
comprised of repeating disaccharide units, 
[-3xylose-α1,3-GlcAβ1-] on α-DG (53). HNK-1ST 
has the ability to transfer a sulfate group to the C-3 
position of terminal GlcA, at which xylose is 
transferred; therefore, it makes sense that HNK-1ST 
inhibits IIH6-reactive glycan produced by LARGE. 
Our data presented in this study are highly important 
for understanding dystroglycan function via its 
glycosylation.  
    In mammals, an apparent molecular weight of 
α-DG varies from highly limited (about 120 kDa, e.g. 
brain) to rather broad (120-200 kDa, e.g. muscle) due 
to its glycosylation in a tissue-dependent manner 
(18,19,21). In contrast, in experiments using cell 
lines, forced expression of LARGE always yields an 
extensively glycosylated α-DG that appears as a 
band of ≥200 kDa on SDS-PAGE (Fig. 2-5) 
(37,38,41), implying the presence of an unidentified 
machinery that negatively regulates the glycosylation 
of α-DG in vivo. Hence, we propose HNK-1ST to be 
one such suppressive factor for α-DG function, 
acting as a “molecular brake” to generate properly 
glycosylated α-DG. In this regard, future studies 
might identify a pathogenic mutation of HNK-1ST in 
CMD patients, which causes hyperactivation of 
HNK-1ST resulting in hypoglycosylation of α-DG. 
Investigating the α-DG-modulating function of 
HNK-1ST could be a powerful means of uncovering 
the regulatory system of α-DG glycosylation, 
contributing to the development of therapeutic 
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FIGURE 1. Altered glycosylation of α-DG associated with HNK-1ST induction in RA-treated 
melanoma cells. (A) RT-PCR was performed using mRNA extracted from S91 cells treated with 
DMSO or 1 µM RA for 16 h. mRNA prepared from 2-week-old mouse brain was used as a positive 
control (PC). (B) The amount of HNK-1ST mRNA was quantified by quantitative RT-PCR, 
normalized to that of GAPDH mRNA, and shown as HNK-1ST/GAPDH. The value for 
DMSO-treated cells was set at one. The graphs indicate the mean ± s.e.m. for three independent 
experiments. **P < 0.01. (C) S91 cells were treated with DMSO or 1 µM RA for the periods 
indicated. The cells were lysed and an equal amount of protein (50 µg) from each sample was 
analyzed by Western blotting with HNK-1 mAb, GP2 (anti-GlcAT-P) pAb, and anti-GAPDH mAb. 
As a positive control for the HNK-1 mAb, GlcAT-P cDNA was transiently transfected into S91 cells 
(GlcAT-P). (D) The migration assay was carried out using transwell chambers with insert membranes 
coated with 10 µg/ml laminin-1. The migration of S91 cells pretreated with DMSO or 1 µM RA for 
48 h was assessed (non). For antibody treatment assays, IIH6 mAb or normal mouse IgG was added 
in the upper chamber (IIH6 and IgG, respectively). The graphs indicate the mean ± s.e.m. for three 
independent experiments (left). ***P < 0.001. The representative Toluidine Blue staining images of 
the insert membranes were shown (right). (E, F) The effect of RA on α-DG was investigated using 
S91 cells treated with DMSO or 1 µM RA for 48 h. (E) Cell surface proteins were biotinylated, pulled 
down by streptavidin-agarose beads, and analyzed by laminin overlay assay or Western blotting with 
IIH6 mAb, anti-β-DG mAb, and α-DG core pAb. (F) Cells were immunostained by IIH6 or anti-β-DG 
mAb. Scale bar; 20 µm. 
 
FIGURE 2. Effect of HNK-1ST knockdown on the glycosylation of α-DG and cell motility. (A) 
S91 cells were treated with DMSO or 1 µM RA for 16 h. mRNA was extracted and subjected to 
RT-PCR analyses using primer sets as indicated. (B) S91 cells were transfected with siRNA and 
treated with DMSO (-) or 1 µM RA (+) for 48 h. Then, cell surface proteins were biotinylated, pulled 
down by streptavidin-agarose beads, and analyzed by laminin overlay assay or Western blotting with 
IIH6 mAb, anti-β-DG mAb, and α-DG core pAb. (C) S91 cells were transfected with siRNA and 
treated with DMSO (-) or 1 µM RA (+) for 16 h. The amount of HNK-1ST mRNA was evaluated by 
quantitative RT-PCR, normalized to that of GAPDH mRNA, and shown as HNK-1ST/GAPDH. The 
value for RA-treated and si-Cont-transfected cells was set at 100. The graphs indicate the mean ± 
s.e.m. for three independent experiments. (D) HNK-1ST-EGFP and LARGE-myc were transiently 
co-expressed in S91 cells as indicated. Then, cell surface proteins were biotinylated, pulled down, and 
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analyzed by laminin overlay assay or Western blotting with IIH6 and anti-β-DG mAb (cell surface). 
Cell lysates were analyzed by Western blotting using anti-myc and anti-EGFP mAbs to assess the 
expression of LARGE-myc and HNK-1ST-EGFP (cell lysate). (E) S91 cells were transfected with 
siRNA and treated with DMSO or 1 µM RA for 48 h, and then subjected to the transwell migration 
assay. The insert membranes were coated with 10 µg/ml laminin-1. The graphs indicate the mean ± 
s.e.m. for three independent experiments. *P < 0.05, ***P < 0.001.  
 
FIGURE 3. Influence of HNK-1ST on the glycosylation and function of α-DG. (A) α-DG-Fc, 
LARGE-myc and HNK-1ST-EGFP were transiently co-expressed in CHO-K1 cells as shown. 
α-DG-Fc was pulled down from the culture medium and assayed for laminin-binding activity by the 
ligand overlay assay and for glycosylation by Western blotting with IIH6 mAb. Anti-Fc pAb was used 
to confirm equal protein loading. *Asterisk indicates non-specific bands. (B) CHO-K1 cell lysates 
were analyzed by Western blotting using anti-myc and anti-EGFP mAbs to assess the expression of 
LARGE-myc and HNK-1ST-EGFP. 
 
FIGURE 4. Effect of other sulfotransferases on the glycosylation of α-DG. (A) CHO-K1 cells were 
co-transfected with α-DG-Fc, LARGE-myc and various EGFP-fused sulfotransferases belonging to 
the HNK-1ST family as indicated. α-DG-Fc was pulled down from the culture medium and analyzed 
by laminin overlay assay and Western blotting with IIH6 mAb and anti-Fc pAb. *Asterisk indicates 
non-specific bands. (B) The expression of LARGE-myc and sulfotransferases was confirmed by 
Western blotting of cell lysates using anti-myc mAb and anti-EGFP mAb. 
 
FIGURE 5. Importance of sulfotransferase activity of HNK-1ST to the α-DG-modulating 
function. (A, B) The requirement of the sulfotransferase activity was investigated using an 
activity-abolished mutant of HNK-1ST (R189A-EGFP). (A) α-DG-Fc, LARGE-myc and wild-type or 
R189A HNK-1ST-EGFP were transiently co-expressed in CHO-K1 cells as shown. α-DG-Fc was 
precipitated from the culture medium and analyzed by laminin overlay assay and Western blotting 
with IIH6 mAb and anti-Fc pAb. *Asterisk indicates non-specific bands. (B) Cell lysates were 
subjected to Western blotting using anti-myc and anti-EGFP mAbs to assess the expression of 
LARGE-myc and wild-type or R189A HNK-1ST-EGFP. (C, D) The importance of the 
sulfotransferase activity was examined by PAPS inhibition experiments using sodium chlorate 
(NaClO3). (C) CHO-K1 cells were transiently transfected with α-DG-Fc, LARGE-myc and 
HNK-1ST-EGFP in combination as indicated, and then treated with NaClO3 for 48 h. α-DG-Fc was 
21 
precipitated from the culture medium and analyzed by laminin overlay assay and Western blotting 
with IIH6 mAb and anti-Fc pAb. *Asterisk indicates non-specific bands. (D) The expression of 
LARGE-myc and HNK-1ST-EGFP was confirmed by Western blotting of CHO-K1 cell lysates using 
anti-myc and anti-EGFP mAbs. 
 
FIGURE 6. HNK-1ST-mediated incorporation of sulfate into α-DG. (A) α-DG-Fc and 
HNK-1ST-EGFP were transiently expressed in CHO-K1 cells as shown. α-DG-Fc was pulled down 
from the cultured medium and analyzed by laminin overlay assay and Western blotting with anti-Fc 
pAb (medium). The cell lysates were subjected to Western blotting using anti-EGFP mAb to assess 
the expression of HNK-1ST-EGFP (cell lysate). *Asterisk indicates non-specific bands. (B) CHO-K1 
cells transiently expressing α-DG-Fc with (+) or without (-) HNK-1ST-EGFP were labeled with 
radioactive [35S]-sodium sulfate. α-DG-Fc was pulled down from the culture medium, separated by 
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